Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorCooper, Caroline-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorKao, Steven-
dc.contributor.authorKlebe, Sonja-
dc.contributor.authorLee, Chee Khoon-
dc.contributor.authorLeong, Trishe Y-M-
dc.contributor.authorMillward, Michael-
dc.contributor.authorO'Byrne, Ken-
dc.contributor.authorRussell, Prudence A-
dc.contributor.authorSolomon, Benjamin-
dc.contributor.authorCooper, Wendy A-
dc.contributor.authorFox, Stephen-
dc.identifier.citationPathology 2019; 51(7): 673-680-
dc.description.abstractLung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58-83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2-39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve.-
dc.subjectNon-small cell lung cancer-
dc.subjectbiomarker testing-
dc.titleAustralian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.-
dc.typeJournal Article-
dc.identifier.affiliationSchool of Medicine, Western Sydney University, Sydney, NSW, Australiaen
dc.identifier.affiliationRoyal Prince Alfred Hospital, Camperdown, NSW, Australiaen
dc.identifier.affiliationSydney Medical School, University of Sydney, Sydney, NSW, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Vic, Australiaen
dc.identifier.affiliationSt Vincent's Hospital, University of Melbourne, Melbourne, Vic, Australiaen
dc.identifier.affiliationPrincess Alexandra Hospital, Woolloongabba, Qld, Australiaen
dc.identifier.affiliationUniversity of Western Australia, Perth, WA, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSt George Hospital, Kogarah, NSW, Australiaen
dc.identifier.affiliationSA Pathology, and Flinders University at Flinders Medical Centre, Bedford Park, SA, Australiaen
dc.identifier.affiliationChris O'Brien Lifehouse, Camperdown, NSW, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationPathology Queensland, Princess Alexandra Hospital, Woolloongabba, Qld, Australiaen
dc.identifier.affiliationRoyal North Shore Hospital, St Leonards, and Sydney University, Camperdown, NSW, Australiaen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.